CAJ | 학술논문

由于抗体所具有的高特异性和亲和力，抗体与肿瘤细胞表面的特异性抗原结合后，可通过不同的生物学作用抑制肿瘤细胞的生长。目前，治疗性抗体已成为肿瘤治疗中的一线治疗策略。截至2013年，美国FDA已批准了14种抗体药物用于临床肿瘤的治疗。随着肿瘤研究的不断深入，越来越多的参与肿瘤发生发展以及导致肿瘤免疫逃逸的分子陆续被发现，以这些分子为靶点，利用针对这些分子的特异性抗体进行肿瘤治疗，已成为目前肿瘤治疗研究的热点，同时也是转化医学最成功的范例之一。
유우항체소구유적고특이성화친화력，항체여종류세포표면적특이성항원결합후，가통과불동적생물학작용억제종류세포적생장。목전，치료성항체이성위종류치료중적일선치료책략。절지2013년，미국FDA이비준료14충항체약물용우림상종류적치료。수착종류연구적불단심입，월래월다적삼여종류발생발전이급도치종류면역도일적분자륙속피발현，이저사분자위파점，이용침대저사분자적특이성항체진행종류치료，이성위목전종류치료연구적열점，동시야시전화의학최성공적범례지일。
With high specificity and affinity,after binding with its specific antigen on tumor cell,antibody can inhibit the growth of tumor cell through different biological functions.Currently,an-tibody has become the first-line treatment strategy in cancer thera-py.Until 2013,14 antibodies have been approved by FDA to be used in clinic for cancer treatment.With the development of canc-er research,more and more molecules that are involved in tumor progression or tumor immune escape have been found,and more and more scientists are working on developing therapeutic antibod-ies targeting these molecules.Therapeutic antibody has become the hot spot in tumor research,and one of the most successful ex-amples in translational medicine.